title: [Chronic liver disease and thrombosis risk].
abstract: The coagulopathy of chronic liver disease involves elevated risks for thrombosis in the portal vein and extra-splanchic sites. Hypercoagulability may moreover accelerate liver fibrosis progression. Cirrhosis-related portal vein thrombosis is associated with decompensation events and inferior prognosis; anticoagulation therapy achieves complete recanalization in -40% of recent thromboses and prevents thrombosis progression in chronic cases. Standard thrombosis prophylaxis seems appropriate for hospitalized cirrhotic patients. This review provides practical guidance to tailoring anticoagulation therapy in cirrhosis according to individual bleeding risk. We also propose an algorithm for using anticoagulation and transjugular intrahepatic portosystemic shunts in the treatment of cirrhotic portal vein thrombosis.
authors.forename: Fredrik
authors.initials: F
authors.lastname: Aberg
authors.forename: Riitta
authors.initials: R
authors.lastname: Lassila
authors.forename: Minna
authors.initials: M
authors.lastname: Ilmakunnas
authors.forename: Kalle
authors.initials: K
authors.lastname: Jokelainen
authors.forename: Kirsti
authors.initials: K
authors.lastname: Numminen
authors.forename: Heikki
authors.initials: H
authors.lastname: Mäkisalo
mesh_terms: D000465:Algorithms; D000925:Anticoagulants / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000150:complications / Q000188:drug therapy; D002908:Chronic Disease; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D011169:Portal Vein; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D011379:Prognosis; D012307:Risk Factors; D020246:Venous Thrombosis / Q000209:etiology* / Q000628:therapy*
chemical_list: D000925:Anticoagulants